Glenmark Life Science informs about resignation of director

22 Apr 2024 Evaluate
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 (‘Listing Regulations’), Glenmark Life Science has informed that Gita Nayyar (DIN: 07128438), has tendered her resignation as a Non-Executive, Independent Director of the Company, with effect from 22nd April, 2024. Consequently, she shall also cease to be a Member of the Nomination & Remuneration Committee of the Company. Further, there are no other material reasons other than those mentioned in the attached resignation letter. The resignation letter received from Gita Nayyar is enclosed. The details required under Regulation 30 of the SEBI Listing Regulations, read with the SEBI Master Circular dated July 11, 2023 and the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, with respect to the resignation of Gita Nayyar is given in Annexure enclosed.

The above information is a part of company’s filings submitted to BSE.

Alivus Life Sciences Share Price

907.15 1.75 (0.19%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×